Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2022, with a report date of February 16, 2022. The document serves as a transaction notification regarding securities purchases by a Person Discharging Managerial Responsibilities (PDMR) and a person closely associated with them (PCA).
Key Financial Metrics
This filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details specific share transactions:
- Transaction 1: Purchase of 15,360 Ordinary Shares (ISIN: GB0009252882) by Mr. James Ford (SVP and General Counsel) at a price of £16.29 per share on February 10, 2022, on the London Stock Exchange.
- Transaction 2: Purchase of 46 American Depositary Shares (ADSs) (ISIN: US37733W1053) by Mr. Joshua Ford (PCA of Mr. James Ford) at a price of $42.93 per share on February 14, 2022, on the New York Stock Exchange.
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It reports only the specific insider trading activities listed above.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is a regulatory disclosure of insider transactions.
Investor Verification Points
- Verify the identity and role of Mr. James Ford (SVP and General Counsel) and his relationship to Mr. Joshua Ford.
- Confirm the transaction dates (February 10 and February 14, 2022) and execution venues (London Stock Exchange and New York Stock Exchange).
- Note that this filing does not provide data on GSK's overall financial performance for the period.